Form 4: X4 Pharmaceuticals Director Keith Woods Reports Acquisition and Disposal of Common Stock

Director Keith Woods reports the acquisition of 45,000 shares of common stock and disposal of 135,000 shares of common stock in X4 Pharmaceuticals, Inc.

Summary

• On June 10, 2024, Keith Woods, a director of X4 Pharmaceuticals, Inc., reported acquiring 45,000 shares of common stock.
• The acquisition was related to restricted stock units (RSUs) granted as an annual award for board service.
• Woods also disposed of 135,000 shares of common stock on the same day.
• Following these transactions, Woods beneficially owns 135,000 shares of X4 Pharmaceuticals, Inc.

Sentiment

Score: 5

Explanation: This is a routine filing related to stock transactions by a company director. It doesn't inherently indicate positive or negative sentiment, but rather provides factual information.

Future Outlook

The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• Shareholders may be interested in the trading activity of company insiders as an indicator of management's confidence in the company's prospects.

Key Dates